Prognostic value of computed tomography derived skeletal muscle mass index in lung cancer: A meta-analysis

Xue-Lin Pan,Hong-Jun Li,Zhen Li,Zhen-Lin Li
DOI: https://doi.org/10.12998/wjcc.v10.i20.6927
2022-01-01
World Journal of Clinical Cases
Abstract:BACKGROUND The prognostic role of the skeletal muscle mass index (SMI) derived from computed tomography (CT) imaging been well verified in several types of cancers. However, whether the SMI could serve as a reliable and valuable predictor of long-term survival in lung cancer patients remains unclear. AIM To identify the prognostic value of the CT-derived SMI in lung cancer patients. METHODS The PubMed, Web of Science, and Embase electronic databases were searched up to November 5, 2021 for relevant studies. The Reference Citation Analysis databases were used during the literature searching and selection. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated to assess the association of the SMI with the overall survival (OS) of lung cancer patients. All statistical analyses were performed with STATA 12.0 software. RESULTS A total of 12 studies involving 3002 patients were included. The pooled results demonstrated that a lower SMI was significantly related to poorer OS (HR = 1.23, 95%CI: 1.11-1.37, P < 0.001). In addition, the subgroup analyses stratified by treatment (nonsurgery vs surgery), tumor stage (advanced stage vs early stage), and tumor type (non-small cell lung cancer vs lung cancer) showed similar results. CONCLUSION The CT-derived SMI is a novel and valuable prognostic indicator in lung cancer and might contribute to the clinical management and treatment of lung cancer patients.
What problem does this paper attempt to address?